Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review

Ustekinumab is approved for the treatment of psoriasis and Crohn’s disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, w...

Full description

Saved in:
Bibliographic Details
Published in:Archives of dermatological research 2022-08, Vol.314 (6), p.503-514
Main Authors: Rawal, Sahil, Kianian, Sara, Guo, William, Marquez, Jocellie, Ayasse, Marissa, Siamas, Katherine A., Lee, Yoojin, Salvemini, Joann
Format: Article
Language:English
Subjects:
Adverse events
Atopic dermatitis
Bullous pemphigoid
Clinical outcomes
Crohn's disease
Dermatology
Eczema
Immunotherapy
Inflammation
Lichen planus
Medicine
Medicine & Public Health
Monoclonal antibodies
Patient safety
Patients
Pityriasis
Psoriasis
Pyoderma
Pyoderma gangrenosum
Review
Sarcoidosis
Side effects
Skin diseases
Systematic review
Systemic lupus erythematosus
Vitiligo
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ustekinumab is approved for the treatment of psoriasis and Crohn’s disease. Because many dermatological conditions are due to immune-mediated development, ustekinumab may be effective in other conditions. A systematic review of the off-label uses of ustekinumab, as well as on-label adverse effect, was performed, reporting on clinical improvement. MEDLINE, Embase, Web of Science, and Cochrane databases were searched for studies regarding ustekinumab treatment of rativa (HS), lichen planus (LP), pyoderma gangrenosum (PG), pityriasis rubra pilaris (PRP), cutalopecia areata (AA), atopic dermatitis (AD), Bechet’s disease, bullous pemphigoid (BP), hidradenitis suppuaneous sarcoidosis, cutaneous systemic lupus erythematosus (SLE), and vitiligo. Descriptive statistics were performed. 74 articles of 4596 screened were included, and reported on 212 patients receiving ustekinumab treatment. Across all studies, ustekinumab showed promise in treating patients: AA (10/12 patients; 83.3% improvement), AD (28/74 patients; 37.8% improvement), HS (42/52 patients; 80.8% improvement), and PRP (25/27 patients; 92.6% improvement), among others. Adverse events were noted with the use of ustekinumab, including development of AA (four patients), AD (three patients), and BP (four patients), among others. Ustekinumab can be a promising option for patients with dermatological conditions refractory to traditional therapies. Adverse events must be monitored in certain patients.
ISSN:1432-069X
0340-3696
1432-069X
DOI:10.1007/s00403-021-02262-7